FDA records list B·R·A·H·M·S GmbH (part of Thermo Fisher Scientific) as applicant for K260302, a Traditional 510(k) for B·R·A·H·M·S MR-proADM KRYPTOR, B·R·A·H·M·S MR-proADM KRYPTOR CAL and B·R·A·H·M·S MR-proADM KRYPTOR QC. The filing carries product code SJQ under regulation number 866.3215 in the Microbiology advisory committee, with a device name describing an immunoassay for host biomarkers to predict risk of 28-day all-cause mortality in patients with sepsis and septic shock. The submission was received on 30 January 2026 and decided on 23 October 2026 as Substantially Equivalent. [1][2]

The MR-proADM KRYPTOR submission

The K260302 record covers three named components: the MR-proADM KRYPTOR assay, a calibrator set (CAL) and a quality-control material (QC). FDA classifies the device as class 2, and the record notes a Summary statement and no third-party review. The applicant address in the filing is Neuendorfstrasse 25, Hennigsdorf, Germany; that is a filing address, not a verified headquarters. [1][2]

Thermo Fisher's own MR-proADM pages describe the assay as measuring a marker of endothelial dysfunction, intended for use alongside clinical evaluation and other laboratory findings in conditions such as infections, sepsis and heart failure. The same publisher lists early assessment of infection severity among stated benefits. These are the manufacturer's characterizations, not independently verified performance results. [8]

Assay components and sample types

A comparison table on the Innolitics record for K260302 sets the MR-proADM KRYPTOR sample type as EDTA plasma, against serum and EDTA or heparin plasma for the predicate column, and pairs it with B·R·A·H·M·S MR-proADM KRYPTOR QC controls. The table is a secondary compilation of the filing, so the underlying submission remains the authoritative document. [2]

The MR-proADM assay appears in Thermo Fisher's biomarker overview as a 50-test kit, article number 829050N, GTIN 4260157632080, listed under Infectiology for the B·R·A·H·M·S KRYPTOR GOLD and KRYPTOR compact PLUS analyzers, with no LOINC code shown. The same overview lists PCT sensitive, Copeptin proAVP, MR-proANP and endocrinology markers as neighboring assays on those instruments. [3][6]

The KRYPTOR analyzer platform

Thermo Fisher describes B·R·A·H·M·S KRYPTOR analyzers as fully automated random-access benchtop immunoanalyzers using TRACE technology, and states that the technology is associated with a Nobel prize. The company presents precision and reliable decisions as product claims on that page. [7]

Consumables and accessories documented by the same publisher include KRYPTOR GOLD solutions for cleaning, dilution and reaction plates, and KRYPTOR Buffer, each with article and GTIN numbers. MR-proADM is also licensed for DiaSorin's LIAISON platform, which Thermo Fisher identifies as a DiaSorin product licensed from Thermo Fisher Scientific. [3][4]

Portfolio scope in the supplied filings

The supplied collection contains one linked 510(k) record, K260302, with a decision count of one Substantially Equivalent and a record sample of the same single entry. That count describes the MedtechLedger snapshot only; it is not a measure of total company sales, total portfolio or safety performance. [1][5]

No premarket approval, recall or other pathway record for this applicant appears in the public information, and no additional clearances are documented here. Whether other B·R·A·H·M·S assays hold separate United States clearances is unknown from these sources. [1][5]